AZD0449, an inhaled JAK1 inhibitor, in healthy participants and patients with mild asthma.

ABSTRACT:

Aims

Inhaled corticosteroids (ICS) plus bronchodilator are recommended for the treatment of asthma. Targeting the JAK1-dependent pathway may be an alternative for asthma management in patients with incomplete response to ICS. The aim of this study was to investigate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of AZD0449, a novel JAK1 selective inhibitor, following inhaled (dry powder, nebulized) and intravenous administration to healthy participants and patients with mild asthma.

Methods

This was a randomized, single-blind, placebo-controlled Phase 1 study (NCT03766399) of single- and multiple-ascending doses conducted using a three-part design. Healthy participants and patients with mild asthma aged 18-55 years were recruited. The study evaluat

SUBMITTER: Lundahl A 

PROVIDER: S-EPMC12746370 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature